Quick navigation menu :

  1. Go to content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the languages menu
  5. Go to the help menu
  6. Go to the slots
  7. Go to the shortcuts list

You are here :

Welcome to the
impact-malaria.com website

Welcome to the
impact-malaria.com website

For several decades, sanofi-aventis has operated in Africa and in malaria endemic countries through its subsidiaries and production units.
Our portfolio includes several antimalarial drugs, ranging from quinine to the fixed-dose combination of artesunate and amodiaquine launched in 2007.

Experts editorial

April 1st, 2008
Pr Masserigne Soumaré, Clinic for Infectious Diseases, Fann National University Hospital (Senegal) gives his views on

Find all the editorials written by experts on malaria:

Content :

News

Sanofi-aventis wins the 2010 Global Business Coalition Core Competence Award for its innovative malaria access to medicines program.

On June 8th, 2010 sanofi-aventis was awarded the 2010 Global Business Coalition Core Competence Award, for its innovative Malaria Access to Medicines partnership program with the Drugs for Neglected Diseases Initiative (DNDi).

 

Plasmodium life-cycle and natural history of malaria

This animation, which illustrates, in six short sequences, the various stages of the life-cycle of the malaria parasite in the human host and in its mosquito vector, has been conceived by Professors Christophe Rogier et Marcel Hommel.

Worrying for WHO

“Drug resistance could set back malaria control succcess” said WHO

Geneva, February 25th, 2009

The MENTOR Initiative

The MENTOR Initiative is a partner of sanofi-aventis in the fight against malaria in humanitarian emergency situations and in the training of local and international policy makers.

 

Slots :

Roll Back MalariaWorld Malaria Day 2009

 

Malaria learning resource

Improve your knowledge of malaria with Marcel Hommel’s further education module

 

Meetings and events

List of congresses and events on Malaria

 
This website complies to the WCAG 1.0 Double-A international accessibility guidelines (details)